Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.

Autor: Gutman JA; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Winters A; Center for Cancer and Blood Disorders, Department of Pediatrics, University of Colorado, Aurora CO., Kent A; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Amaya M; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., McMahon C; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Smith C; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Jordan CT; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Stevens B; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Minhajuddin M; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Pei S; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Schowinsky J; Department of Pathology, University of Colorado, Aurora CO., Tobin J; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., O'Brien K; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Falco A; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Taylor E; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Brecl C; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Zhou K; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Ho P; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Sohalski C; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Dell-Martin J; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Ondracek O; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO., Abbott D; Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, University of Colorado, Aurora CO., Pollyea DA; Division of Hematology, Department of Medicine, University of Colorado, Aurora CO. Daniel.pollyea@ucdenver.edu.

Publikováno v: Haematologica [Haematologica] 2023 Oct 01; Vol. 108 (10), pp. 2616-2625. Date of Electronic Publication: 2023 Oct 01.

Prototype system for phase advance measurements of LHC small beam oscillations

Autor: Olexa, J, Ondracek, O, Brezovic, Z, Gasior, M

Magnet lattice parameters of the Large Hadron Collider (LHC) are measured by exciting beam transverse oscillations that allow measuring their phase advance using the beam position measurement (BPM) system. However, the BPM system requires millimetre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od________65::6c068a14fbf3399cd7b3922d7a34c749
http://cds.cern.ch/record/1546401

Integrated radio communication systems based on IT.

Autor: Gasparik, I., Ondracek, O.

Publikováno v: 2009 19th International Conference Radioelektronika; 2009, p11-16, 6p

Tissue Parameters Influence on the Microwave Energy Absorption in Biological Objects.

Autor: Surda, J., Cocherova, E., Ondracek, O.

Publikováno v: 2008 14th Conference on Microwave Techniques; 2008, p1-4, 4p

Full Field Fourier Domain Optical Coherence Tomography.

Autor: Grajciar, B., Ondracek, O.

Publikováno v: 2006 International Conference on Applied Electronics; 2006, p47-50, 4p